Tolerance of camel*s milk and mare*s milk in cow*s milk protein allergy.

Published: 20-02-2012 Last updated: 01-05-2024

Primary: To establish the tolerance of camel*s milk and mare*s milk in standardized food provocation tests in patients with double-blind placebo-controlled provocation (DBPCP) proven CMA >=3 years of age. Secondary: To determine the minimum...

Ethical review Approved WMO

Status Pending

Health condition type Other condition **Study type** Interventional

Summary

ID

NL-OMON39043

Source

ToetsingOnline

Brief title

The PAKA study.

Condition

Other condition

Synonym

cow's milk allergy

Health condition

voedselallergiëen

Research involving

Human

Sponsors and support

Primary sponsor: Benemel en Smits Kamelenmelk

Source(s) of monetary or material Support: Benemel; Smits

Kamelenmelk;Syntens;Eureka;5-sterrenregio.

Intervention

Keyword: Allergy, Camel's milk, Cow's milk, Mare's milk

Outcome measures

Primary outcome

Tolerance of camel*s and mare*s milk, as determined by provocation tests.

Secondary outcome

1. the minimum eliciting dose of camel*s milk and mare*s milk in CMA patients who do not tolerate these milk(s) in standardized food provocation tests; 2. medium-term (four weeks) tolerance of camel*s and/or mare*s milk in those participants who were negative in the provocation tests; 3. long-term (6-12 months) tolerance of camel*s and/or mare*s milk in those participants who were advised they could go on consuming the milk(s); 4. titer and affinity of specific IgE in serum to cow*s milk, camel*s milk and mare*s milk at the start of the study, and after four weeks of daily consumption of camel*s and/or mare*s milk; 5. the patients'experience with the consumption of camel's milk and mare's milk.

Study description

Background summary

Cow*s milk protein allergy (CMA) is a common problem in young infants, but can also occur in older children and adults. Camel*s milk and mare*s milk proteins

2 - Tolerance of camel*s milk and mare*s milk in cow*s milk protein allergy. 5-05-2025

differ considerably from those in cow*s milk. Therefore they might be tolerated by patients with CMA, as has been shown in a few small studies.

Study objective

Primary: To establish the tolerance of camel*s milk and mare*s milk in standardized food provocation tests in patients with double-blind placebo-controlled provocation (DBPCP) proven CMA >=3 years of age. Secondary: To determine the minimum eliciting dose of camel*s milk and mare*s milk in CMA patients who do not tolerate these milk(s) in standardized food provocation tests; to investigate medium-term (4 weeks) and long-term (6-12 months) tolerance of camel*s milk and mare*s milk in CMA patients who do tolerate these milk(s) in standardized food provocation tests; to determine the titer and affinity of specific IgE to cow*s milk, and the titer and affinity of specific IgE to camel*s milk and mare*s milk before introduction, and after 4 weeks of daily ingestion in the CMA patients who tolerate these milk(s) in standardized food provocation tests. The patients'experience with the consumption of these milks will be analysed in a short questionnaire.

Study design

Randomized cross-over intervention trial.

Intervention

Participants are randomized to receive increasing doses of either camel*s milk or mare*s milk in a standardized provocation test. One to four weeks later the participants who first received camel*s milk, receive mare*s milk, or the reverse. Participants who did not show allergic reactions to one milk will consume that milk daily for four weeks; participants who did not show allergic reactions to both milks will be randomized to receive camel*s milk or mare*s milk daily during four weeks, and the other milk during the four weeks thereafter. If no allergic symptoms occur during those four weeks, participants are advised that they can go on consuming this milk if they want to. At 6-12 months after study entry, participants who had been advised they could go on consuming one or both milks will be asked to answer a questionnaire on their experiences with these milks.

Study burden and risks

Patients who should be considered as high-risk for DBPCP are excluded from participation. A maximum of five study visits take place (at inclusion, during the 2 provocation tests for camel*s milk and mare*s milk in the day care hospital, and - if applicable - after the four weeks of daily camel*s milk and mare*s milk consumption). Venepuncture is performed 0-3 times, depending on the presence of left-over material before the study, and the reactions in the

provocation tests (when both are positive, the study stops). A diary is completed daily to record symptoms during 2-10 weeks.

Contacts

Public

Benemel en Smits Kamelenmelk

Benemel: Graafsebaan 3. Smits Kamelenmelk: Werstkant 16. 0

Benemel: 5411RE Zeeland. Smits Kamelenmelk: 5258 TC Berlicum. 0

NL

Scientific

Benemel en Smits Kamelenmelk

Benemel: Graafsebaan 3. Smits Kamelenmelk: Werstkant 16. 0

Benemel: 5411RE Zeeland. Smits Kamelenmelk: 5258 TC Berlicum. 0

NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years) Adolescents (16-17 years) Adults (18-64 years) Children (2-11 years) Elderly (65 years and older)

Inclusion criteria

Cow's milk protein allergy proven by double-blind placebo-controlled provocation; >=3 years of age.

Exclusion criteria

Experienced a life-threatening reaction to a food allergen; instable asthma.

Study design

Design

Study type: Interventional

Intervention model: Crossover

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-01-2012

Enrollment: 31

Type: Anticipated

Ethics review

Approved WMO

Date: 20-02-2012

Application type: First submission

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 06-06-2012

Application type: Amendment

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 13-01-2014

Application type: Amendment

en Proefpersonen (Tilburg)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL38223.028.11